News

Video

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Author(s):

Steven M. Horwitz, MD

Steven Horwitz, MD, presents the final results of the Phase 2 PRIMO trial, highlighting the efficacy and safety of duvelisib as a promising treatment option for relapsed/refractory peripheral T-cell lymphoma, with insights into overall response rates, progression-free survival, and adverse event management.

Related Videos
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Related Content
Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com
December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 12th 2024

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

HMA-Naive Chronic Myelomonocytic Leukemia | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
December 11th 2024

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET